Study combination treatment before surgery for high-risk acral melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old and can give informed consent.
- You have confirmed acral melanoma that is stage 2 or stage 3.
- You have not started any anti-cancer treatment that works throughout the body (such as immunotherapy, chemotherapy, targeted therapy).
- Your cancer has measurable signs doctors can track (meets RECIST 1.1 criteria).
- Your general health score is ECOG 0–1 (you are up and about most of the time).
- You must have adequate heart, liver, kidney, and blood function, and be expected to live more than 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
This trial tests two medicines given before surgery to shrink stage III–IV acral melanoma (a melanoma type on the hands/feet) and improve outcomes. If the tumors respond, surgery can happen afterward as planned.
This trial tests whether giving two drugs (QL1706 and OH2) before and after surgery can help treat stage III acral melanoma, a type of skin cancer on the palms, soles, or under nails. The goal is to see if this approach reduces the chance of the cancer coming back.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
This trial tests whether giving a combination of three immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. It is for people whose melanoma can be surgically removed, and the goal is to see if this approach is safe and effective.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.